ATE395087T1 - Hgf zur gentherapie der karidomyopathie - Google Patents

Hgf zur gentherapie der karidomyopathie

Info

Publication number
ATE395087T1
ATE395087T1 AT00964686T AT00964686T ATE395087T1 AT E395087 T1 ATE395087 T1 AT E395087T1 AT 00964686 T AT00964686 T AT 00964686T AT 00964686 T AT00964686 T AT 00964686T AT E395087 T1 ATE395087 T1 AT E395087T1
Authority
AT
Austria
Prior art keywords
hgf
caridomyopathy
gene therapy
cardiac muscle
cardiac
Prior art date
Application number
AT00964686T
Other languages
English (en)
Inventor
Ryuichi Morishita
Yoshiaki Taniyama
Toshio Ogihara
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE395087T1 publication Critical patent/ATE395087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00964686T 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie ATE395087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28853299 1999-10-08

Publications (1)

Publication Number Publication Date
ATE395087T1 true ATE395087T1 (de) 2008-05-15

Family

ID=17731468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964686T ATE395087T1 (de) 1999-10-08 2000-10-05 Hgf zur gentherapie der karidomyopathie

Country Status (10)

Country Link
US (1) US6989374B1 (de)
EP (1) EP1136083B1 (de)
JP (1) JP3865632B2 (de)
KR (1) KR20010093804A (de)
CN (2) CN101085363A (de)
AT (1) ATE395087T1 (de)
AU (1) AU775965B2 (de)
CA (1) CA2354029C (de)
DE (1) DE60038869D1 (de)
WO (1) WO2001026694A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ315769A (en) * 1995-08-29 1999-05-28 Sumitomo Pharma Lioposomal composition containing hepatocyte growth factor (hgf)
PT1142590E (pt) * 1999-10-29 2008-10-27 Anges Mg Inc Terapêutica génica para doença isquémica diabética
JP2005097118A (ja) * 2000-07-18 2005-04-14 Yoshiki Sawa Ｈｇｆ遺伝子からなる細胞移植定着促進剤
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002089854A1 (fr) 2001-05-09 2002-11-14 Anges Mg, Inc. Transfert de genes et facteur angiogenique pour maladie de la peau
EP1435977A4 (de) 2001-09-19 2005-06-08 Ford Henry Health System Herztransplantation von stammzellen zur behandlung von herzinsuffizienz
JP4441263B2 (ja) 2001-11-28 2010-03-31 アンジェスＭｇ株式会社 神経変性疾患遺伝子治療剤
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
WO2004030702A1 (ja) 2002-10-02 2004-04-15 Anges Mg, Inc. 聴覚機能障害用医薬
WO2004089400A1 (ja) * 2003-04-01 2004-10-21 Yasuhiko Tabata 心筋症治療剤
JPWO2006046766A1 (ja) * 2004-10-29 2008-05-22 アンジェスＭｇ株式会社 心不全治療のための遺伝子治療
US7696170B2 (en) 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
CN101200721B (zh) * 2006-09-18 2011-06-08 复旦大学附属中山医院 人心肌保护基因及其用途
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
WO2009073594A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2009073616A2 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
JP4831551B2 (ja) * 2008-11-06 2011-12-07 国立大学法人名古屋大学 非虚血性心筋障害に対する医薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
EP0461560B1 (de) 1990-06-11 1998-11-18 Toshikazu Nakamura Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
EP0819014B1 (de) * 1995-03-30 2003-02-05 Heartport, Inc. Endovaskulärerkatheter zum ableiten aus dem herz
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
NZ315769A (en) * 1995-08-29 1999-05-28 Sumitomo Pharma Lioposomal composition containing hepatocyte growth factor (hgf)
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
KR100768023B1 (ko) 1999-09-21 2007-10-17 안제스에무지 가부시키가이샤 뇌혈관 장애를 위한 유전자 치료
PT1142590E (pt) 1999-10-29 2008-10-27 Anges Mg Inc Terapêutica génica para doença isquémica diabética
EP1532987A4 (de) 2002-06-06 2005-12-28 Anges Mg Inc Mittel für die gentherapie bei zerebrovaskulären erkrankungen

Also Published As

Publication number Publication date
US6989374B1 (en) 2006-01-24
DE60038869D1 (de) 2008-06-26
KR20010093804A (ko) 2001-10-29
CN1293922C (zh) 2007-01-10
AU775965B2 (en) 2004-08-19
CN1337884A (zh) 2002-02-27
WO2001026694A1 (fr) 2001-04-19
CN101085363A (zh) 2007-12-12
EP1136083B1 (de) 2008-05-14
EP1136083A1 (de) 2001-09-26
EP1136083A4 (de) 2005-11-16
CA2354029A1 (en) 2001-04-19
JP3865632B2 (ja) 2007-01-10
CA2354029C (en) 2012-01-10
AU7556900A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
DE60038869D1 (de) Hgf zur gentherapie der karidomyopathie
PE22996A1 (es) Derivados 5-substituidos del acido micofenolico
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FI961755A0 (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
CY1106733T1 (el) Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
HK1014497A1 (en) Therapeutic uses of bactericidal/permeability increasing protein products
ATE232396T1 (de) Oxydiertes thymosin beta 4
WO2003045332A3 (en) Methods and compositions for treating lesions of the respiratory epithelium
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1108667T1 (el) Ανασυνδυασμενοι φορεις ιου περιεχοντες το ανθρωπινο γονιδιο του ενεργοποιητη πλασμινογονου ουροκινασης και η χρηση τους στην αγωγη της ινωσεως του ηπατος.
WO2000040273A3 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
NO984052D0 (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
ATE296894T1 (de) Genverabreichende vektoren mit gewebetropismus für glatte muskelzellen und/oder endothelzellen
DK1790655T3 (da) Biologisk aktive peptider
EA200200319A1 (ru) Белок iren, его получение и использование
DE60019104D1 (de) Gentherapy von lungenkrankheiten
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors
ATE248920T1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie
AU2001268108A1 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PT1103270E (pt) Tratamento de doencas auto-imunes em mamiferos
WO2001019850A3 (en) Nrage nucleic acids and polypeptides and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties